Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Sunitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,221Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cogent Biosciences Files NDA for Bezuclastinib Under RTOR
    Cogent Biosciences Files NDA for Bezuclastinib Under RTOR

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221679/0/en/Cogent-Biosciences-to-Initiate-New-Drug-Application-NDA-Submission-for-Bezuclastinib-Under-Real-Time-Oncology-Review-RTOR.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Cogent Eyes FDA Approval After Clearing Another Ph. 3 Hurdle
    Cogent Eyes FDA Approval After Clearing Another Ph. 3 Hurdle

    12 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cogent-eyes-fda-submission-cancer-asset-after-clearing-another-phase-3-hurdle

    FIERCE BIOTECH
    12 Nov 2025
    Share Share
    Stomach Cancer Awareness Month
    Stomach Cancer Awareness Month

    01 Nov 2025

    // PRESS RELEASE

    https://www.nanoalvand.com/index.php/en/blog-en/9-news/215-stomach-cancer-awareness-month

    PRESS RELEASE
    01 Nov 2025
    Share Share
    Enforcement Report - Week of December 11, 2024
    Enforcement Report - Week of December 11, 2024

    11 Dec 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-11-2024-90405.pdf

    FDA
    11 Dec 2024
    Share Share
    Eugia`s Generic Sunitinib Malate Receives Approval in the U.S.
    Eugia`s Generic Sunitinib Malate Receives Approval in the U.S.

    14 Mar 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218615

    FDA
    14 Mar 2024
    Share Share
    Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
    Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

    22 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240122188361/en

    BUSINESSWIRE
    22 Jan 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.